Curatis Holding AG
Curatis Holding AG is a biopharmaceutical company focused on the development and commercialization of regenerative medicine products, primarily in the field of orthopedics and musculoskeletal disorders.
Business. Curatis Holding AG (CURN.S) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the healthcare sector, focusing on product sales as its primary revenue model. Specific details regarding operating segments and geographic distribution are not available. The company is listed under the ticker CURN.S.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Curatis Holding AG (CURN.S) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the healthcare sector, focusing on product sales as its primary revenue model. Specific details regarding operating segments and geographic distribution are not available. The company is listed under the ticker CURN.S.
Curatis operates with a capital structure that is entirely equity-funded, as evidenced by a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company maintains a current ratio of 1.65, suggesting it has sufficient short-term assets to cover its liabilities, though its liquidity position is categorized as low due to negative operating and free cash flows of -CHF1.31 million and -CHF2.25 million, respectively.
Profitability metrics are negative, with a return on equity (ROE) of -3.07% and a return on assets (ROA) of -2.53%, both significantly below the industry median for pharmaceutical firms, which typically exhibit positive ROE and ROA figures. This underperformance is driven by a net loss of CHF1.42 million and an operating loss of CHF1.51 million, despite a gross profit of CHF2.84 million.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segmental or geographic detail limits the ability to assess exposure to regional market risks or growth opportunities.
Looking ahead, the company is projected to maintain a negative growth trajectory, with no positive revenue deltas reported in the outlook. Historical revenue of CHF10.8 million is expected to remain flat or decline in the near term, constrained by ongoing operating losses and limited capital expenditure of -CHF1.22 million.
Risk factors include low liquidity and the absence of immediate dilution pressures, as no filing-based flags were detected. However, the company's reliance on equity financing and negative cash flows from operations suggest potential future dilution if additional capital is required to fund operations or R&D.
Recent events include the continued development of its lead product, Curnatide, for the treatment of osteoarthritis, with no major regulatory or clinical milestones disclosed in the latest filings. The company remains in the clinical development phase, with no commercial products currently generating revenue.
- Curatis is an equity-funded biopharmaceutical company with no long-term debt and a low liquidity position.
- The company is unprofitable, with negative ROE and ROA, and is operating at a loss despite generating gross profit.
- Revenue is concentrated in a single segment, with no geographic diversification disclosed.
- The company is in the clinical development phase, with no commercial products and a negative cash flow position.
- No immediate dilution or liquidity risks are flagged, but ongoing losses may necessitate future capital raises.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Curatis Holding AG Market data — financials · 2026-05-27
Ownership & reference
Leadership
- Roland RutschmannChief Executive Officer, Executive Director